CATAPRES TAB 0.1MG TABLET

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

CLONIDINE HYDROCHLORIDE

Предлага се от:

BOEHRINGER INGELHEIM (CANADA) LTD LTEE

АТС код:

C02AC01

INN (Международно Name):

CLONIDINE

дозиране:

0.1MG

Лекарствена форма:

TABLET

Композиция:

CLONIDINE HYDROCHLORIDE 0.1MG

Начин на приложение:

ORAL

Броя в опаковка:

100

Вид предписание :

Prescription

Терапевтична област:

CENTRAL ALPHA-AGONISTS

Каталог на резюме:

Active ingredient group (AIG) number: 0108891001; AHFS:

Статус Оторизация:

CANCELLED POST MARKET

Дата Оторизация:

2017-02-15

Данни за продукта

_Catapres_
_®_
_ Product Monograph _
_Page 1 of 29_
PRODUCT MONOGRAPH
PR
CATAPRES
®
(Clonidine Hydrochloride)
Boehringer Ingelheim Standard
TABLETS
0.1
mg, 0.2 mg
Antihypertensive
Boehringer Ingelheim (Canada) Ltd
5180 South Service Road
Burlington, Ontario
L7L 5H4
Date of Revision:
June 21, 2012
SUBMISSION CONTROL NO: 154435
Catapres
®
is a registered trademark used under license by Boehringer Ingelheim
(Canada) Ltd.
CCDS 0067-03
_ _
_Catapres_
_®_
_ Product Monograph _
_Page 2 of 29 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................11
OVERDOSAGE
................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
............................................................13
STORAGE AND STABILITY
..........................................................................................15
DOSAGE FORMS, COMPOSITION AND
PACKAGING.............................................15
PART II: SCIENTIFIC INFORMATION
...............................................................................16
PHARMACEUTICAL INFORMATION
..........................................................................16
DET